Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

The treatment of cancer patients has dramatically changed over the past decades with the
advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved
for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and …

Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2)
are associated with the development of many tumors. It is currently a crucial treatment for …

Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of
a wide range of solid tumors. The targeted nature of these biotherapeutics has improved …

Rapid growth of nanotechnology is one of the most quickly emerging tendencies in cancer
therapy. Gold nanoparticles roused a distinctive interest in the field, due to their …